banter and General Discussion, page-4887

Originally posted by col69
I wonder how all this is progressing with Mesoblast and Cartherics partnership given Cartherics just received a $5.4 million grant from the Medical Research Futures Fund (MRFF) ?


Cartherics is delighted to announce we have received a $5.4 million Medical Research Futures Fund (MRFF) to advance our research into a new approach to enhance cancer therapy by engaging the patients’ own immune system to complement CAR cell therapy.






View attachment 4725856

It might be absolutely nothing but following on from my post above on 30 September 2022, Cartherics was today awarded its first USA patent .....

The Cartherics patent covers a number of things including word for word what the 2018 Mesoblast immunotherapies partnership announcement does ''allogeneic off the shelf" CAR-T cells .... Hmmm - the plot thickens


"It provides protection for both autologous (patient-derived) and allogeneic (off-the-shelf) immune cell products that carry the TAG-72 CAR."





https://cartherics.com/news/cartherics-granted-first-us-patent-for-multiple-development-candidates/

Cartherics granted first US patent for multiple development candidates


Melbourne, Australia, 06 October 2022 – Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has been granted US patent 11,400,145, entitled “Genetically modified cells and uses thereof”.

This patent provides a proprietary position for multiple development candidates in Cartherics’ pipeline. Specifically, this patent covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T cells bearing the TAG-72 CAR. It provides protection for both autologous (patient-derived) and allogeneic (off-the-shelf) immune cell products that carry the TAG-72 CAR.

TAG-72 is highly expressed on a range of adenocarcinomas, including ovarian and gastric cancers. Issuance of the patent is an important milestone in the development of new treatments for these cancers.

Cartherics’ initial target indication is relapsed or refractory ovarian cancer, where greater than 90 percent of tumors are TAG-72 positive. Targeting these tumors with novel cellular immunotherapies will help address the unmet need for new treatment options for these patients.

Professor Alan Trounson, CEO of Cartherics, said, “This patent is the first US patent to issue from Cartherics’ substantial and growing intellectual property portfolio. It reflects Cartherics’ commitment to the development of novel and innovative cellular immunotherapies for the treatment of cancer.”